M&A Deal Summary |
|
---|---|
Date | 2007-02-16 |
Target | Praecis Pharmaceuticals |
Sector | Life Science |
Buyer(s) | GSK |
Deal Type | Add-on Acquisition |
Deal Value | 55M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1715 |
Sector | Life Science |
Employees | 70,212 |
Revenue | 30.3B GBP (2023) |
GSK is a multinational pharmaceutical, biologics, vaccines and consumer healthcare company. GSK was founded in 1715 and is based in Brentford, United Kingdom.
DEAL STATS | # |
---|---|
Overall | 8 of 32 |
Sector (Life Science) | 7 of 26 |
Type (Add-on Acquisition) | 6 of 24 |
State (Maine) | 1 of 1 |
Country (United States) | 6 of 19 |
Year (2007) | 1 of 2 |
Size (of disclosed) | 27 of 28 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2006-12-08 |
Domantis
Cambridge, United Kingdom Domantis has pioneered the next generation of antibody therapy, which is based on the smallest functional binding units of human antibodies. These units, termed domain antibodies (dAbs), may be administered in inhaled, topical, and, potentially, oral formulations as well as by injection and infusion. The Domantis technology also enables dAbs to serve as building blocks for therapeutics simultaneously directed at more than one disease target. |
Buy | £230M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2007-12-19 |
Reliant Pharmaceuticals
Liberty Corner, New Jersey, United States Reliant Pharmaceuticals, Inc. is a pharmaceutical company. |
Buy | $1.7B |